[HTML][HTML] Successful long-term monotherapy with rituximab in a patient with chronic lymphocytic leukemia of the B-cell-lineage: a case report
I Sturm, J Oertel, S Oertel, J Westermann… - Journal of Medical Case …, 2008 - Springer
Introduction Treatment of chronic lymphocytic leukemia of the B-cell-lineage is strongly
based upon clinical staging because of the heterogeneous clinical course of this disease …
based upon clinical staging because of the heterogeneous clinical course of this disease …
[HTML][HTML] Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to …
DR Howard, T Munir, L McParland… - Health Technology …, 2017 - europepmc.org
Background The conventional frontline therapy for fit patients with chronic lymphocytic
leukaemia (CLL) is fludarabine, cyclophosphamide and rituximab (FCR). Rituximab …
leukaemia (CLL) is fludarabine, cyclophosphamide and rituximab (FCR). Rituximab …
B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities
RJ Hill, Y Lou, SL Tan - International Reviews of Immunology, 2013 - Taylor & Francis
B-cell chronic lymphocytic leukemia (CLL) is characterized by clonally expanded and
molecularly heterogeneous populations of B lymphocytes with impaired apoptotic …
molecularly heterogeneous populations of B lymphocytes with impaired apoptotic …
[HTML][HTML] Preliminary results of a phase 1b study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously …
I Flinn, M Brunvand, MJS Dyer, P Hillman, J Jones… - Blood, 2014 - Elsevier
Introduction Despite progress in chronic lymphocytic leukemia (CLL) treatment, new
therapies are needed especially for relapsed/refractory (R/R) patients (pts). BCL2 is an anti …
therapies are needed especially for relapsed/refractory (R/R) patients (pts). BCL2 is an anti …
Rituximab-based chemoimmunotherapy prolongs survival of patients with chronic lymphocytic leukemia independently of the time of administration
Background The combination of purine analogues (PA) and rituximab (
chemoimmunotherapy) is considered the treatment of choice for CLL. The aim of this study …
chemoimmunotherapy) is considered the treatment of choice for CLL. The aim of this study …
[HTML][HTML] Rituximab plus chlorambucil as initial treatment for elderly patients with chronic lymphocytic leukemia (CLL): effect of pre-treatment biological characteristics …
R Foa, S Ciolli, F Di Raimondo, G Del Poeta, F Lauria… - Blood, 2011 - Elsevier
Abstract 294 Rituximab plus fludarabine/cyclophosphamide (R-FC) is currently the standard
of care for fit patients with untreated or relapsed CLL. However, patients with CLL are …
of care for fit patients with untreated or relapsed CLL. However, patients with CLL are …
The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein–kinase–dependent …
IM Pedersen, AM Buhl, P Klausen… - Blood, The Journal …, 2002 - ashpublications.org
Antibodies against CD20 can activate complement and induce antibody-dependent cellular
cytotoxicity (ADCC) in B lymphocytes. In B-cell lines, such antibodies also induce apoptosis …
cytotoxicity (ADCC) in B lymphocytes. In B-cell lines, such antibodies also induce apoptosis …
[HTML][HTML] Rituximab maintenance in patients with chronic lymphocytic leukemia (CLL) after upfront treatment with rituximab plus fludarabine, cyclophosphamide, and …
F Bosch, P Abrisqueta, N Villamor, MJ Terol… - Blood, 2011 - Elsevier
Abstract 293 The effectiveness of rituximab, fludarabine, cyclophosphamide, and
mitoxantrone (R-FCM) followed by rituximab maintenance in the treatment of CLL has been …
mitoxantrone (R-FCM) followed by rituximab maintenance in the treatment of CLL has been …
Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia
J Li, J Zhi, M Wenger, N Valente… - The Journal of …, 2012 - Wiley Online Library
This retrospective analysis characterizes rituximab population pharmacokinetics in
combination with fludarabine and cyclophosphamide and its effect on fludarabine and …
combination with fludarabine and cyclophosphamide and its effect on fludarabine and …
[HTML][HTML] Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) …
T Robak, SI Moiseev, A Dmoszynska, P Solal-Céligny… - Blood, 2008 - Elsevier
The addition of rituximab to a variety of chemotherapy regimens for the treatment of patients
with CLL has yielded promising results in phase II trials. The R-FC regimen demonstrated …
with CLL has yielded promising results in phase II trials. The R-FC regimen demonstrated …